Black Diamond Therapeutics, Inc.
BDTX
$1.71
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | -- | -- | -- |
| SG&A Expenses | -38.35% | -39.67% | -31.32% | -31.79% | -4.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.95% | -36.37% | -28.54% | -25.16% | -13.08% |
| Operating Income | -1,046.54% | 125.22% | 114.57% | 105.39% | 95.30% |
| Income Before Tax | -948.77% | 132.10% | 129.41% | 117.93% | 106.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -948.77% | 132.10% | 129.41% | 117.93% | 106.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -948.77% | 132.10% | 129.41% | 117.93% | 106.38% |
| EBIT | -1,046.54% | 125.22% | 114.57% | 105.39% | 95.30% |
| EBITDA | -1,147.04% | 125.75% | 115.06% | 105.81% | 95.68% |
| EPS Basic | -1,056.94% | 131.32% | 127.88% | 116.51% | 104.65% |
| Normalized Basic EPS | -1,051.57% | 140.27% | 126.30% | 115.34% | 103.82% |
| EPS Diluted | -1,451.24% | 129.42% | 126.13% | 114.78% | 103.32% |
| Normalized Diluted EPS | -1,394.75% | 138.92% | 125.04% | 114.22% | 102.81% |
| Average Basic Shares Outstanding | 1.39% | 3.37% | 5.53% | 8.13% | 17.83% |
| Average Diluted Shares Outstanding | 0.94% | 3.82% | 6.00% | 8.61% | 18.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |